Kornerup H J, Pedersen E B, Christensen N J, Pedersen A, Pedersen G
Eur J Clin Pharmacol. 1979 Nov;16(5):305-10. doi: 10.1007/BF00605626.
Arterial blood pressure and plasma catecholamines, renin activity and aldosterone concentration in 12 patients with severe essential hypertension were studied before and after combined alpha- and beta-adrenergic receptor blockage induced by oral labetalol treatment for 2 months. Furosemide in a fixed dose was employed as a basic antihypertensive agent throughout the study. Blood pressure was adequately controlled in only 6 patients. Mean body weight increased by 1.8 kg and there was a rise in body weight which was inversely correlated with the fall in standing mean blood pressure. The mean plasma noradrenaline concentration decreased from 0.30 to 0.20 ng/ml, whereas plasma adrenaline did not change significantly. Plasma renin activity and aldosterone concentration varied greatly, but the mean values did not change significantly. Change in body weight was correlated inversely with changes in plasma noradrenaline and renin. The results suggest that labetalol, through its combined alpha- and beta-adrenergic receptor blocking action, induces a rise in body weight, probably due to sodium and fluid retention, which partly counterbalances the antihypertensive effect of labetalol, and partly modifies both renin and sympathetic nervous activity.
对12例重度原发性高血压患者,在口服拉贝洛尔联合α和β肾上腺素能受体阻滞剂治疗2个月前后,研究其动脉血压、血浆儿茶酚胺、肾素活性和醛固酮浓度。在整个研究过程中,使用固定剂量的呋塞米作为基础降压药。仅6例患者的血压得到充分控制。平均体重增加了1.8千克,体重增加与站立位平均血压下降呈负相关。血浆去甲肾上腺素平均浓度从0.30纳克/毫升降至0.20纳克/毫升,而血浆肾上腺素无明显变化。血浆肾素活性和醛固酮浓度变化很大,但平均值无明显改变。体重变化与血浆去甲肾上腺素和肾素的变化呈负相关。结果表明,拉贝洛尔通过其联合的α和β肾上腺素能受体阻断作用,导致体重增加,可能是由于钠和液体潴留,这部分抵消了拉贝洛尔的降压作用,并部分改变了肾素和交感神经活性。